Shattuck Labs Inc (STTK) Stock Price, Quote & News

Company Profile

Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study. It is also...

Industry: Biotechnology

Sector: Healthcare

Phone: 512 900 4690

Website: www.shattucklabs.com

Address:

500 West 5th Street, Suite 1200, Austin, United States

prismmarketview Aug. 11 at 3:15 PM

$STTK reported positive Phase 1 results for SL-325, a potentially first-in-class DR3-blocking antibody. In the multiple-ascending-dose cohort, the candidate showed durable DR3 receptor occupancy at all doses and was generally well tolerated. Phase 2b in Crohn’s is next. https://prismmarketview.com/shattuck-labs-q2-2026-sl-325-advances-toward-phase-2-crohns-disease-study/

0 · Reply

StocktwitsEarnings Aug. 11 at 12:15 PM

$STTK Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.12 up 50.00% YoY • Shattuck Labs expects that current cash and cash equivalents and short-term investments of approximately $208.3 million as of June 30, 2026, will be sufficient to fund operations into 2029.

0 · Reply

focafoca99 Aug. 11 at 10:28 AM

$STTK disclosed Q2 2026 results with promising Phase 1 SL-325 data and $208M cash runway into 2029.

0 · Reply

NyseDayTrader Aug. 4 at 6:02 PM

$STTK This is gearing up for a breakout

0 · Reply

IN0V8 Jul. 24 at 2:20 PM

$STTK Opportunity JP Morgan initiates coverage with overweight rating JP Morgan initiates price target $10

0 · Reply

NyseDayTrader Jul. 23 at 10:59 PM

$STTK consolidation at the $6.70 to $7.40 range is real. Waiting for the next leg up.

0 · Reply

StockScanners Jul. 18 at 8:30 AM

$STTK keep watch this holds above 7.27

0 · Reply

StockScanners Jul. 17 at 4:51 AM

$STTK reached 7.20

0 · Reply

NyseDayTrader Jul. 16 at 8:09 PM

$HYFT $STTK $SPCX $GSBD Current. LETS GO!!!

0 · Reply

NyseDayTrader Jul. 16 at 8:03 PM

$STTK holding 12k strong on this one

0 · Reply

Shattuck Labs price target lowered to $14 from $18 at H.C. Wainwright

Aug 11, 2026, 7:00 AM EDT - 8 days ago

Shattuck Labs Quarterly report: Q2 2026

Aug 11, 2026, 7:00 AM EDT - 8 days ago

Shattuck Labs Earnings release: Q2 2026

Aug 11, 2026, 7:00 AM EDT - 8 days ago

Shattuck Labs Slides: Corporate presentation

2026-08-11T10:20:32.000Z - 8 days ago

Shattuck Labs reports Q2 EPS (12c), consensus (12c)

2026-07-24T08:45:08.000Z - 26 days ago

Shattuck Labs initiated with an Overweight at JPMorgan

2026-07-20T12:15:16.000Z - 4 weeks ago

Shattuck Labs initiated with an Outperform at Leerink

2026-07-20T10:25:43.000Z - 4 weeks ago

Shattuck Labs initiated with an Outperform at Leerink

Jul 14, 2026, 9:00 AM EDT - 5 weeks ago

Shattuck Labs Slides: Corporate presentation

2026-06-10T10:05:44.000Z - 2 months ago

Shattuck Labs 10.9M share Spot Secondary priced at $4.00

Jun 10, 2026, 12:21 AM EDT - 2 months ago

Shattuck Labs, Inc. Announces Pricing of $75 Million Public Offering

2026-06-09T20:30:52.000Z - 2 months ago

Shattuck Labs TBA Spot Secondary; price range $4.00-$4.25

2026-06-09T20:20:20.000Z - 2 months ago

Shattuck Labs announces common stock offering, no amount given

Jun 9, 2026, 4:18 PM EDT - 2 months ago

Shattuck Labs, Inc. Announces Proposed Public Offering

Jun 9, 2026, 8:00 AM EDT - 2 months ago

Shattuck Labs Announces Exercise of Outstanding Common Stock Warrants and Provides Financial Update

2026-06-09T09:55:40.000Z - 2 months ago

Shattuck Labs price target raised to $18 from $7 at Citi

2026-06-08T15:20:25.000Z - 2 months ago

Shattuck Labs price target raised to $17 from $14 at Needham

Jun 8, 2026, 8:00 AM EDT - 2 months ago

Shattuck Labs Transcript: Study result

Jun 8, 2026, 8:00 AM EDT - 2 months ago

Shattuck Labs Press release: Study result

Jun 8, 2026, 8:00 AM EDT - 2 months ago

Shattuck Labs Slides: Study result

2026-06-08T10:10:51.000Z - 2 months ago

Shattuck Labs announces Phase 1 results for SL-325

Jun 8, 2026, 6:00 AM EDT - 2 months ago

Shattuck Labs Announces Phase 1 Results for SL-325

Jun 5, 2026, 4:05 PM EDT - 2 months ago

Shattuck Labs to Host Investor Call and Webcast on Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update on June 8

2026-06-05T09:55:07.000Z - 2 months ago

Citi opens ‘upside 30-day catalyst watch’ on Shattuck into data

2026-06-05T01:05:18.000Z - 2 months ago

Shattuck Labs upgraded to Buy from Neutral at Citi

2026-05-08T13:46:57.000Z - 3 months ago

Shattuck Labs price target raised to $11 from $8 at Wedbush

2026-05-07T16:39:16.000Z - 3 months ago

Shattuck Labs reports Q1 EPS (13c), consensus (13c)

2026-05-07T16:38:04.000Z - 3 months ago

Shattuck Labs sees cash and cash equivalents sufficient into 2029

May 7, 2026, 7:00 AM EDT - 3 months ago

Shattuck Labs Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 3 months ago

Shattuck Labs Earnings release: Q1 2026

May 7, 2026, 7:00 AM EDT - 3 months ago

Shattuck Labs Slides: Corporate presentation

May 7, 2026, 6:15 AM EDT - 3 months ago

Shattuck Labs Reports First Quarter 2026 Financial Results and Recent Business Highlights

2026-04-27T11:35:53.000Z - 4 months ago

Shattuck Labs initiated with an Overweight at Cantor Fitzgerald

Apr 8, 2026, 8:00 AM EDT - 4 months ago

Shattuck Labs Proxy statement: Proxy filing

Apr 8, 2026, 8:00 AM EDT - 4 months ago

Shattuck Labs Proxy statement: Proxy filing

Mar 5, 2026, 7:00 AM EST - 5 months ago

Shattuck Labs Slides: Corporate presentation

Mar 5, 2026, 6:30 AM EST - 5 months ago

Shattuck Labs Annual report: Q4 2025

Mar 5, 2026, 6:30 AM EST - 5 months ago

Shattuck Labs Earnings release: Q4 2025

Mar 5, 2026, 6:15 AM EST - 5 months ago

Shattuck Labs Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Highlights

Mar 2, 2026, 9:10 AM EST - 6 months ago

Shattuck Labs Transcript: TD Cowen 46th Annual Health Care Conference

Feb 25, 2026, 8:00 AM EST - 6 months ago

Shattuck Labs Announces Participation in Upcoming March Investor Conferences

Feb 6, 2026, 8:30 AM EST - 6 months ago

Shattuck Labs Announces Participation in Upcoming Piper Sandler Virtual Novel Targets in Immunology Symposium

Jan 13, 2026, 7:00 AM EST - 7 months ago

Shattuck Labs Registration statement: Registration Filing

Dec 15, 2025, 4:15 PM EST - 8 months ago

Shattuck Labs, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 4, 2025, 8:20 AM EST - 9 months ago

Shattuck Labs Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 2, 2025, 10:10 AM EST - 9 months ago

Shattuck Labs Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 20, 2025, 8:00 AM EST - 9 months ago

Shattuck Labs to Participate in Upcoming December Investor Conferences

Nov 6, 2025, 4:30 PM EST - 10 months ago

Shattuck Labs Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov 6, 2025, 7:00 AM EST - 10 months ago

Shattuck Labs Earnings release: Q3 2025

Nov 6, 2025, 7:00 AM EST - 10 months ago

Shattuck Labs Quarterly report: Q3 2025

Nov 6, 2025, 2:00 AM EST - 10 months ago

Shattuck Labs Slides: Corporate Presentation

Oct 8, 2025, 10:00 AM EDT - 11 months ago

Shattuck Labs Transcript: The United European Gastroenterology (UEG) Congress UEG Week 2025

Oct 2, 2025, 7:51 AM EDT - 11 months ago

Shattuck Labs Announces Participation in Upcoming Wedbush Securities Key Opinion Leader (KOL) and Company Panel

Sep 18, 2025, 8:00 AM EDT - 11 months ago

Shattuck Labs Registration statement: Registration Filing

Aug 26, 2025, 6:30 AM EDT - 1 year ago

Shattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of Directors

Aug 21, 2025, 10:17 AM EDT - 1 year ago

Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel Disease

Aug 14, 2025, 4:00 PM EDT - 1 year ago

Shattuck Labs Earnings release: Q2 2025

Aug 14, 2025, 4:00 PM EDT - 1 year ago

Shattuck Labs Quarterly report: Q2 2025

Aug 14, 2025, 6:30 AM EDT - 1 year ago

Shattuck Labs Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Aug 5, 2025, 6:30 AM EDT - 1 year ago

Shattuck Labs Announces Oversubscribed Private Placement of Up to Approximately $103 Million

Jul 2, 2025, 7:00 AM EDT - 1 year ago

Shattuck Labs Announces Participation in Upcoming Leerink Partners Therapeutics Forum: I&I and Metabolism

May 21, 2025, 8:00 AM EDT - 1 year ago

Shattuck Labs Proxy statement: Proxy Filing

May 21, 2025, 8:00 AM EDT - 1 year ago

Shattuck Labs Proxy statement: Proxy Filing

May 1, 2025, 4:20 PM EDT - 1 year ago

Shattuck Labs Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 1, 2025, 7:00 AM EDT - 1 year ago

Shattuck Labs Slides: Corporate Presentation

Apr 30, 2025, 6:00 PM EDT - 1 year ago

Shattuck Labs Quarterly report: Q1 2025

Apr 30, 2025, 6:00 PM EDT - 1 year ago

Shattuck Labs Earnings release: Q1 2025

Apr 9, 2025, 3:00 PM EDT - 1 year ago

Shattuck Labs Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 2, 2025, 5:00 PM EDT - 1 year ago

Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference

Mar 27, 2025, 8:00 AM EDT - 1 year ago

Shattuck Labs Slides: Corporate presentation

Mar 27, 2025, 7:00 AM EDT - 1 year ago

Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights

Mar 26, 2025, 7:00 PM EDT - 1 year ago

Shattuck Labs Earnings release: Q4 2024

Mar 26, 2025, 7:00 PM EDT - 1 year ago

Shattuck Labs Annual report: Q4 2024

Feb 20, 2025, 9:00 AM EST - 1 year ago

Shattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025

Feb 13, 2025, 4:30 PM EST - 1 year ago

Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025

Feb 4, 2025, 7:00 AM EST - 1 year ago

Shattuck Labs Announces Poster Presentation at Upcoming 2025 Crohn's and Colitis Congress

Jan 16, 2025, 10:30 AM EST - 1 year ago

Shattuck Labs Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 6, 2025, 4:59 PM EST - 1 year ago

Shattuck Labs Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 2, 2025, 7:00 AM EST - 1 year ago

Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2025

Dec 4, 2024, 8:45 AM EST - 1 year ago

Shattuck Labs Transcript: 7th Annual Evercore ISI HealthCONx Healthcare Conference

Dec 3, 2024, 12:30 PM EST - 1 year ago

Shattuck Labs Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 14, 2024, 7:00 AM EST - 1 year ago

Shattuck Labs Quarterly report: Q3 2024

Nov 14, 2024, 7:00 AM EST - 1 year ago

Shattuck Labs Earnings release: Q3 2024

Nov 14, 2024, 7:00 AM EST - 1 year ago

Shattuck Labs Slides: Corporate presentation

Oct 1, 2024, 12:23 PM EDT - 2 years ago

Shattuck Labs' stock craters as biotech scraps main product candidate after failed trial

Oct 1, 2024, 8:00 AM EDT - 2 years ago

Shattuck Labs Transcript: Study Update

Oct 1, 2024, 8:00 AM EDT - 2 years ago

Shattuck Labs Press release: Study Update

Oct 1, 2024, 8:00 AM EDT - 2 years ago

Shattuck Labs Slides: Study Update

Oct 1, 2024, 7:00 AM EDT - 2 years ago

Shattuck Labs Slides: Corporate Presentation

Oct 1, 2024, 6:30 AM EDT - 2 years ago

Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway

Aug 1, 2024, 9:30 AM EDT - 2 years ago

Shattuck Labs Quarterly report: Q2 2024

Aug 1, 2024, 9:30 AM EDT - 2 years ago

Shattuck Labs Earnings release: Q2 2024

Aug 1, 2024, 7:00 AM EDT - 2 years ago

Shattuck Labs Slides: Corporate Presentation

Jul 30, 2024, 5:00 PM EDT - 2 years ago

Shattuck Labs Announces Participation in Upcoming BTIG Virtual Biotechnology Conference

Jul 1, 2024, 6:00 AM EDT - 2 years ago

Shattuck Labs Announces Addition to Russell 2000® and Russell 3000® Indexes

Jun 14, 2024, 12:00 PM EDT - 2 years ago

Shattuck Labs Transcript: Study Update

Jun 14, 2024, 12:00 PM EDT - 2 years ago

Shattuck Labs Press release: Study Update

Jun 14, 2024, 12:00 PM EDT - 2 years ago

Shattuck Labs Slides: Study Update

Jun 14, 2024, 6:00 AM EDT - 2 years ago

Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leuk

prismmarketview Aug. 11 at 3:15 PM

0 · Reply

StocktwitsEarnings Aug. 11 at 12:15 PM

0 · Reply

focafoca99 Aug. 11 at 10:28 AM

$STTK disclosed Q2 2026 results with promising Phase 1 SL-325 data and $208M cash runway into 2029.

0 · Reply

NyseDayTrader Aug. 4 at 6:02 PM

$STTK This is gearing up for a breakout

0 · Reply

IN0V8 Jul. 24 at 2:20 PM

$STTK Opportunity JP Morgan initiates coverage with overweight rating JP Morgan initiates price target $10

0 · Reply

NyseDayTrader Jul. 23 at 10:59 PM

$STTK consolidation at the $6.70 to $7.40 range is real. Waiting for the next leg up.

0 · Reply

StockScanners Jul. 18 at 8:30 AM

$STTK keep watch this holds above 7.27

0 · Reply

StockScanners Jul. 17 at 4:51 AM

$STTK reached 7.20

0 · Reply

NyseDayTrader Jul. 16 at 8:09 PM

$HYFT $STTK $SPCX $GSBD Current. LETS GO!!!

0 · Reply

NyseDayTrader Jul. 16 at 8:03 PM

$STTK holding 12k strong on this one

0 · Reply

StockScanners Jul. 16 at 4:19 AM

$STTK keep watch if this holds above 6.59

0 · Reply

AlertsAndNews Jul. 15 at 6:57 PM

$STTK interesting options flow here. ITM strikes got hits a minutes ago.

1 · Reply

NyseDayTrader Jul. 3 at 9:26 AM

Most investors wait for confirmation. By then, the easy money is usually gone. THE OPPORTUNITY ISN’T AFTER EVERYONE AGREES. IT’S BEFORE THEY DO. $HYFT $STTK

0 · Reply

Win4PopPop Jul. 1 at 8:45 PM

$PSKY Look what the UK just did with $GETY & $STTK . UK is a dumpster fire.

0 · Reply

NyseDayTrader Jun. 30 at 2:32 PM

$STTK I'm SUPER bullish on this ticker

0 · Reply

NyseDayTrader Jun. 30 at 1:15 AM

$STTK Anyone else watching STTK? The volume has been anything but normal. You had the 5.5M share day… then Friday drops 12.2M shares. Add in those late-day spikes into the close, and it definitely makes you wonder. Could be funds loading Or… is someone positioning ahead of something bigger? Buyout? 😉 I’m not chasing. I’m already here.

0 · Reply

NyseDayTrader Jun. 29 at 9:15 PM

$STTK Its obvious its how you finish that counts

0 · Reply

StockScanners Jun. 27 at 6:04 PM

$STTK keep watch if this holds above 6.29

0 · Reply

NyseDayTrader Jun. 26 at 8:59 PM

$STTK 12.2 million today!

0 · Reply

NyseDayTrader Jun. 26 at 3:28 PM

$STTK is starting to look real interesting. Here's what I'm seeing... 💰 Around **$220M** available to fund operations. 👊 Insiders didn't just talk—they bought with their own money. 📈 June wasn't normal. A **5.5M+ share trading day** followed by trading volume that appeared to run at roughly **double the stock's recent average**. That's not an accident. Somebody was paying attention. Now the company has the cash to execute, insiders have skin in the game, and the tape is finally waking up. I'd rather be early than chase it after everyone suddenly decides they "found" it. My money is already where my conviction is. $STTK 🚀

0 · Reply

ozzarch Jun. 25 at 6:37 PM

$STTK okay lets don't wreck a great week

0 · Reply

NyseDayTrader Jun. 25 at 6:11 PM

$STTK added more here

0 · Reply

Market Cap	566.67M
Revenue (ttm)	1.00M
Net Income (ttm)	-48.81M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-4,881.00%
Debt to Equity Ratio	0.00

Volume	517,000
Avg Vol	1,503,392
Day's Range	N/A - N/A
Shares Out	76.68M
Stochastic %K	55%
Beta	1.08
Analysts	Strong Sell
Price Target	$14.25